Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BVSNYSE:INSPNASDAQ:IRTCNASDAQ:NARI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBVSBioventus$6.82-2.8%$6.71$5.73▼$14.38$560.22M0.84431,357 shs428,692 shsINSPInspire Medical Systems$127.11-1.1%$141.04$123.00▼$225.00$3.79B1.25552,902 shs772,901 shsIRTCiRhythm Technologies$139.22-2.3%$141.36$55.92▼$157.13$4.55B1.41482,772 shs481,300 shsNARIInari Medical$79.97$79.97$39.76▼$79.99$4.68B1.021.44 million shsN/A10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBVSBioventus0.00%+5.52%+6.79%-13.62%+22.54%INSPInspire Medical Systems0.00%-3.06%-5.43%-14.25%-8.86%IRTCiRhythm Technologies0.00%-7.98%-2.94%+42.12%+43.07%NARIInari Medical0.00%0.00%0.00%0.00%+55.61%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBVSBioventus3.3686 of 5 stars3.40.00.00.02.14.21.3INSPInspire Medical Systems4.8309 of 5 stars4.41.00.04.83.02.51.9IRTCiRhythm Technologies1.0639 of 5 stars2.51.00.00.02.20.80.6NARIInari MedicalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBVSBioventus 2.75Moderate Buy$13.75101.61% UpsideINSPInspire Medical Systems 2.73Moderate Buy$211.9166.71% UpsideIRTCiRhythm Technologies 2.90Moderate Buy$138.60-0.45% DownsideNARIInari Medical 2.14Hold$69.22-13.44% DownsideCurrent Analyst Ratings BreakdownLatest BVS, NARI, INSP, and IRTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/7/2025BVSBioventusCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$12.006/11/2025IRTCiRhythm TechnologiesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$130.00 ➝ $160.005/22/2025IRTCiRhythm TechnologiesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$130.00 ➝ $167.005/7/2025BVSBioventusCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$15.005/6/2025INSPInspire Medical SystemsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$220.00 ➝ $200.005/6/2025INSPInspire Medical SystemsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$235.00 ➝ $195.005/6/2025INSPInspire Medical SystemsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$195.00 ➝ $174.005/6/2025INSPInspire Medical SystemsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$230.00 ➝ $236.005/2/2025IRTCiRhythm TechnologiesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$152.00 ➝ $139.005/2/2025IRTCiRhythm TechnologiesRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$133.00 ➝ $150.005/2/2025IRTCiRhythm TechnologiesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$104.00 ➝ $130.00(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBVSBioventus$567.70M0.99$0.54 per share12.58$2.80 per share2.44INSPInspire Medical Systems$802.80M4.67$1.69 per share75.20$23.01 per share5.52IRTCiRhythm Technologies$591.84M7.51N/AN/A$2.90 per share48.01NARIInari Medical$493.63M9.48$0.09 per share906.95$8.07 per share9.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBVSBioventus-$156.23M-$0.48N/A14.83N/A-7.11%15.61%4.01%N/AINSPInspire Medical Systems$53.51M$2.1758.5839.481.977.92%10.00%8.68%8/5/2025 (Estimated)IRTCiRhythm Technologies-$113.29M-$3.14N/AN/AN/A-15.90%-101.04%-9.55%7/30/2025 (Estimated)NARIInari Medical-$1.64M-$1.35N/A727.00N/A-13.68%-10.09%-6.60%N/ALatest BVS, NARI, INSP, and IRTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2025Q1 2025INSPInspire Medical Systems-$0.23$0.10+$0.33$0.10$194.89 million$201.32 million5/1/2025Q1 2025IRTCiRhythm Technologies-$0.89-$0.95-$0.06-$0.97$153.39 million$158.68 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBVSBioventusN/AN/AN/AN/AN/AINSPInspire Medical SystemsN/AN/AN/AN/AN/AIRTCiRhythm TechnologiesN/AN/AN/AN/AN/ANARIInari MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBVSBioventus1.851.410.99INSPInspire Medical SystemsN/A9.017.44IRTCiRhythm Technologies7.475.715.58NARIInari MedicalN/A1.771.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBVSBioventus62.94%INSPInspire Medical Systems94.91%IRTCiRhythm TechnologiesN/ANARIInari Medical90.98%Insider OwnershipCompanyInsider OwnershipBVSBioventus33.00%INSPInspire Medical Systems2.30%IRTCiRhythm Technologies0.68%NARIInari Medical10.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBVSBioventus1,20082.14 million54.46 millionNot OptionableINSPInspire Medical Systems1,24629.49 million28.82 millionOptionableIRTCiRhythm Technologies2,00031.92 million31.71 millionOptionableNARIInari Medical80058.54 million52.34 millionOptionableBVS, NARI, INSP, and IRTC HeadlinesRecent News About These CompaniesFDA grants 510(k) clearance to Stryker’s total ankle systemJune 26, 2025 | medicaldevice-network.comMRoute 92 Medical Appoints Medtech Industry Veterans Mitch Hill and Lucas Buchanan to its Board of DirectorsJune 18, 2025 | finance.yahoo.comAmerican Century Small Cap Growth Fund Q1 2025 CommentaryJune 11, 2025 | seekingalpha.comThrombectomy system removes clots, improves quality of life for patients with PEMay 20, 2025 | healio.comHThe top nitinol cardiac medtech news of 2025 (so far)May 13, 2025 | medicaldesignandoutsourcing.comMStryker outlines 2025 growth targets with 8.5%-9.5% organic sales growth and $13.20-$13.45 EPSMay 2, 2025 | msn.comExpert Testimony Supporting POPR Can Be An Effective StrategyApril 21, 2025 | jdsupra.comVolta Medical Appoints Bill Hoffman as Executive Chairman of the Board of DirectorsApril 8, 2025 | finance.yahoo.com8 spine, orthopedic acquisitions in Q1March 27, 2025 | beckersspine.comBOkami Medical Announces Portfolio Expansion with the Addition of the SENDERO® MAX Delivery CatheterMarch 26, 2025 | finance.yahoo.comHow Is Inari Medical Inc. (NASDAQ:NARI) Positioned in the Medical Devices Sector?March 25, 2025 | kalkinemedia.comKIf You Could Only Hold 3 Investments for Life, Consider These (NARI)...March 10, 2025 | marketbeat.comStryker’s Inari Medical Launches Artix Thrombectomy SystemMarch 7, 2025 | evtoday.comEStryker’s Inari Medical launches Artex thrombectomy systemMarch 7, 2025 | massdevice.comInari Medical introduces thrombectomy system for arterial thrombus casesMarch 7, 2025 | msn.comInari Medical acquisition could provide Stryker with foothold in peripheral vascular marketFebruary 28, 2025 | expresshealthcare.inEWearable defibrillator maker Kestra Medical plots $150M IPOFebruary 26, 2025 | fiercebiotech.comFStryker grows cardiovascular division with Inari Medical acquisitionFebruary 24, 2025 | medicaldevice-network.comMStryker Completes Acquisition of InariFebruary 20, 2025 | evtoday.comEStryker concludes Inari Medical acquisition for $4.9bnFebruary 20, 2025 | finance.yahoo.comStryker completes Inari Medical acquisitionFebruary 20, 2025 | beckersspine.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIs Lululemon’s 18% Selloff Overdone? Analysts Say YesBy Gabriel Osorio-Mazilli | June 9, 2025View Is Lululemon’s 18% Selloff Overdone? Analysts Say Yes330% Returns YTD: Is CoreWeave's Momentum Softening?By Nathan Reiff | June 18, 2025View 330% Returns YTD: Is CoreWeave's Momentum Softening?BVS, NARI, INSP, and IRTC Company DescriptionsBioventus NYSE:BVS$6.82 -0.20 (-2.85%) As of 04:00 PM EasternBioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.Inspire Medical Systems NYSE:INSP$127.11 -1.37 (-1.07%) Closing price 03:59 PM EasternExtended Trading$126.88 -0.23 (-0.18%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.iRhythm Technologies NASDAQ:IRTC$139.22 -3.25 (-2.28%) Closing price 04:00 PM EasternExtended Trading$140.30 +1.08 (+0.78%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.Inari Medical NASDAQ:NARI$79.97 0.00 (0.00%) As of 02/19/2025Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
